A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia

Journal of Clinical Pathology

Volumn 61, Issue 7, 2008, Pages 863-865

  Khorashad, J S ^a   Thelwell, N ^b   Milojkovic, D ^a   Marin, D ^a   Watson, J A ^b   Goldman, J M ^a   Apperley, J F ^a   Foroni, L ^a   Reid, A G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b DxS Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DILUTION; DISEASE SEVERITY; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; EVALUATION STUDY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROCEDURES; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

DNA, COMPLEMENTARY; DNA, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POINT MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 47049084496     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2008.056804     Document Type: Article

References (10)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53.
2. Hehlmann R, Hochhaus A, Baccarani M. European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-50.
3. Milojkovic D, Apperley J. State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 2008;20:112-21.
4. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29.
5. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
6. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658-63.
7. Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999;17:804-7.
8. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
9. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-28.
10. Soverini S, Martinelli G, Amabile M, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. ClinChem 2004;50:1205-13.